Premium
Self‐Adjuvanting Multicomponent Cancer Vaccine Candidates Combining Per‐Glycosylated MUC1 Glycopeptides and the Toll‐like Receptor 2 Agonist Pam 3 CysSer
Author(s) -
Wilkinson Brendan L.,
Day Stephanie,
Malins Lara R.,
Apostolopoulos Vasso,
Payne Richard J.
Publication year - 2011
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201006115
Subject(s) - glycopeptide , agonist , muc1 , toll like receptor , toll , medicine , receptor , microbiology and biotechnology , immunology , cancer , biology , innate immune system , antibiotics
More sugar with your “T” : The title candidates comprising per‐glycosylated MUC1 peptides, a T‐cell helper peptide, and an immunoadjuvant were assembled in high yields using iterative pentafluorophenyl ester‐mediated fragment condensations. Following immunological evaluation, a tricomponent vaccine bearing clustered glycosylation with the T‐antigen was identified (see structure) which elicited high IgG antibody titers in murine models without an external adjuvant.